Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | lutetium Lu 177 dotatate + Triapine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Triapine | 3-AP|3-Apct|OCX-191|OCX 191|OCX191 | Triapine is an inhibitor of ribonucleotide reductase that blocks DNA synthesis, which potentially reduces cell viability and inhibits tumor growth (PMID: 10692563). | ||
lutetium Lu 177 dotatate | Lutathera | LuTate|177Lu-Octreotate|177 Lu-DOTA-Tyr3-octreotate | Lutathera (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog which may selectively kill somatostatin receptor-positive tumor cells (PMID: 28076709). Lutathera (lutetium Lu 177 dotatate) is FDA approved for use in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05724108 | Phase II | lutetium Lu 177 dotatate lutetium Lu 177 dotatate + Triapine | Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT04234568 | Phase I | lutetium Lu 177 dotatate + Triapine | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | Active, not recruiting | USA | 0 |